Platelet counts as a biomarker in ANCA-associated vasculitis

Willeke, P.; Kümpers, Philipp; Schlüter, B.; Limani, Armend; Becker, H; Schotte, Heiko

doi:10.3109/03009742.2015.1006247

Cited by 34 publications

(33 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the contrary, research on platelet (PLT) counts, which are an acknowledged inflammatory marker, found elevated PLT counts in patients with active disease, compared to patients in remission, and also elevated PLT counts in AAV patients with active disease, compared to AAV patients with infection, thus highlighting their role as an AAV specific marker of disease activity [15].…”

Section: Biomarkers In Aavmentioning

confidence: 99%

Biomarkers in Renal Vasculitis

Arseniou¹,

Stai²,

Stangou³

2019

Glomerulonephritis and Nephrotic Syndrome

View full text Add to dashboard Cite

The use of biomarkers in glomerular diseases has been subject of investigation during the last decades, as it can provide worthwhile evidence in diagnosis, but also, it can guide treatment and give information about prognosis and response. Renal biopsy is still the compulsory technique to establish diagnosis, and also to offer information about the severity of renal damage. However, as an invasive method, it cannot be regularly performed during follow up, so the need to find and establish measurement of molecules, easily collected, which are associated with disease pathogenesis and predict renal function outcome seems very attractive to nephrologists. The renal complications of systemic vasculitis are very important for the outcome of the disease, and several substances and molecules, such as inflammatory cells, autoantibodies, cytokines, chemokines and growth factors are produced and may serve as biomarkers to provide useful information for diagnosis, follow up of the disease.

show abstract

Section: Biomarkers In Aavmentioning

confidence: 99%

Biomarkers in Renal Vasculitis

Arseniou¹,

Stai²,

Stangou³

2019

Glomerulonephritis and Nephrotic Syndrome

View full text Add to dashboard Cite

show abstract

“…В свою очередь, активированные тромбоциты могут инициировать запуск системы комплемента путем повышения синтеза С3а, С3b и формирования C5аb-9 [46]. В пользу этой гипотезы свидетельствует и высокая частота развития тромбоцитоза у пациентов с активными формами ААВ, а также взаимосвязь числа тромбоцитов с показателями активности заболевания [47].…”

Section: взаимосвязь тромбоэмболических осложнений и системы комплемеunclassified

Complement in ANCA-associated vasculitis: from pathogenesis to treatment

Zykova¹,

Vinogradova²,

Shchegoleva³

et al. 2019

CPT

View full text Add to dashboard Cite

“…Increasing studies demonstrate a high prevalence of venous thromboembolic event (VTE) and a hypercoagulant state in AAV patients [ 6 – 11 ]. In the active stage of AAV, the platelet count is usually elevated [ 10 , 12 ]. In addition to their classic hemostatic role, platelets are also inflammation protagonists [ 13 – 16 ].…”

Section: Introductionmentioning

confidence: 99%

“…Platelets and the soluble molecules that they secrete can mediate inflammatory responses and thus contribute to vascular injury [ 17 , 18 ]. An association between some platelet indices, including platelet counts, mean platelet volume, and disease activity have been reported in AAV and several other autoimmune diseases, such as inflammatory bowel disease, ankylosing spondylitis and rheumatoid arthritis [ 10 , 12 , 19 – 21 ].…”

Section: Introductionmentioning

confidence: 99%

Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

Miao

Chen

et al. 2017

Arthritis Res Ther

View full text Add to dashboard Cite

BackgroundIn this study, we investigated the mechanism of platelet activation in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), as well as the activation of the alternative complement pathway by platelets in AAV.MethodsCD62P and platelet-leukocyte aggregates in AAV patients were tested by flow cytometry. Platelets were stimulated by plasma from active AAV patients. The effect of the thrombin-protease-activated receptors (PARs) pathway was evaluated by blocking thrombin or PAR1 antagonists. After platelets were activated by plasma from AAV patients, Ca/Mg-Tyrode’s buffer and Mg-EGTA buffer were used to measure complement activation in liquid phase and on the surface of platelets.ResultsThe levels of CD62P-expressing platelets and platelet-leukocyte aggregates were significantly higher in active AAV patients than those in remission and normal controls. Platelets were activated by plasma from active AAV patients (percentage of CD62P-expressing platelets, 97.7 ± 3% vs. 1 ± 0.2%, p < 0.0001, compared with those incubated with healthy donor plasma), and this was inhibited by thrombin or PAR1 antagonists (percentage of CD62P-expressing platelets, 97.7 ± 3% vs. 2.7 ± 1%, p < 0.0001, 97.7 ± 3% vs. 5 ± 1.4%, p < 0.0001, respectively). Platelets activated by plasma from AAV patients could trigger complement activation via the alternative pathway, as demonstrated by significant elevation of C3a, C5a, and sC5b-9 and significantly more C3c and C5b-9 deposition on the surface of platelets.ConclusionsPlatelets were activated in AAV patients, and such activation was at least partially attributed to the thrombin-PARs pathway. Activated platelets triggered the alternative complement pathway in AAV.

show abstract

Platelet counts as a biomarker in ANCA-associated vasculitis

Abstract: PLT counts were found to correlate with disease activity in AAV and thus may be used to represent immunological activity. In addition, PLT counts serve as a marker that can distinguish acute infection from active disease.

Cited by 34 publications

References 26 publications

Biomarkers in Renal Vasculitis

Biomarkers in Renal Vasculitis

Complement in ANCA-associated vasculitis: from pathogenesis to treatment

Platelets are activated in ANCA-associated vasculitis via thrombin-PARs pathway and can activate the alternative complement pathway

Contact Info

Product

Resources

About